Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3826 with DOI

11 strong · 19 moderate · 8 weak

Compilations

12026-05-03T21:29:31.166Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

34last ruled 2026-06-04

0 awaiting a ruling

Issued documents

42026-10-19T20:32:53.399Z

notice · info card · emergency

Searches

181 with no results

queries and counts on the build

Claims checked

10181 supported

81 supported · 20 not

Correspondence

0received

consent field ships in Phase 4

Edges

305

derivations recorded for this entity

Complete over 38 sources, 1 compilation, and 34 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/methcathinone/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-09-24srcCathinone derivatives: a review of their chemistry, pharmacology and toxicology.
  3. 2026-09-24srcDecoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs.
  4. 2026-09-24srcEffects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.
  5. 2026-09-24srcThe Toxicology of Bath Salts: A Review of Synthetic Cathinones
  6. 2026-09-24srcSubstituted methcathinones differ in transporter and receptor interactions
  7. 2026-09-24srcAnalysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse.
  8. 2026-09-24srcPharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.
  9. 2026-09-24srcAcute effects of methcathinone and manganese in mice: A dose response study.
  10. 2026-09-24srcIdentification and quantification of synthetic cathinones in blood and urine using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry
  11. 2026-09-24srcUrine as a material for evaluation of exposure to manganese in methcathinone users.
  12. 2026-09-24srcInvestigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats.
  13. 2026-09-24srcWhite matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.
  14. 2026-09-24srcCocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.
  15. 2026-09-24srcMethcathinone Neurotoxicity in the Rat Prefrontal Cortex by Integrated Synaptic Changes and Transcriptome Analysis.
  16. 2026-09-24srcIncreased reflection impulsivity in patients with ephedrone-induced Parkinsonism.
  17. 2026-09-24srcManganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up.
  18. 2026-09-24srcThe outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology.
  19. 2026-09-24srcPharmacological characterization of designer cathinones in vitro
  20. 2026-09-24srcAbuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin.
  21. 2026-09-24srcEvaluation of cognitive characteristics of patients developing manifestations of parkinsonism secondary to long-term ephedrone use.
  22. 2026-09-24srcManganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report.
  23. 2026-09-24srcCharacteristic of neuropsychological deficits in patients diagnosed with manganese encephalopathy due to ephedrone use - case series analysis.
  24. 2026-09-24srcManganese and Parkinson's Disease: A Critical Review and New Findings.
  25. 2026-09-24srcEmerging drugs of abuse: current perspectives on substituted cathinones
  26. 2026-09-24srcDetermination of Methcathinone in Urine by GC-MS.
  27. 2026-09-24srcManganese-Induced Parkinsonism due to Ephedrone Abuse.
  28. 2026-09-24srcIn vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates.
  29. 2026-09-24srcEphedron dependence--case report.
  30. 2026-09-24srcEncephalopathy caused by intravenous potassium permanganate used for illegal production of methcathinone (ephedrone) from medicines containing pseudoephedrine.
  31. 2026-09-24srcGrey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome.
  32. 2026-09-24srcMethcathinone: a new and potent amphetamine-like agent.
  33. 2026-09-24srcMethcathinone ("cat"): an enantiomeric potency comparison.
  34. 2026-09-24srcNeurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse.
  35. 2026-09-24srcReduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428
  36. 2026-09-24srcDiscriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse.
  37. 2026-09-24srcSynthetic cathinones: an updated harms assessment (GOV.UK, ACMD)
  38. 2026-09-24srcSynthetic cathinones — UNODC substance group listing
  39. 2026-09-24srcMethcathinone DEA Emergency Scheduling (58 FR 25934)
  40. 2026-09-04issueIssued emergency
  41. 2026-09-04issueIssued info_card
  42. 2026-09-04issueIssued notice
  43. 2026-06-04proposal32 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  44. 2026-06-04publicationPublication — backfill
  45. 2026-05-03revisionRevision 1
  46. 2026-05-03absenceSearched ClinicalTrials.gov for "methcathinone" — no results
  47. 2026-05-03genGeneration — pipeline-v5 · with 3 morepipeline-v5
  48. 2026-05-03rungeneration run

The same entries, as forms: six forms.